As of 2026-03-22, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 10.9x | 8.7x |
| Forward P/E multiples | 12.2x - 13.7x | 12.6x |
| Fair Price | (22.86) - (20.75) | (20.35) |
| Upside | -726.2% - -668.6% | -657.6% |
| Date | EV/EBITDA |